Fusion Antibodies (FAB) Competitors

Fusion Antibodies (LON:FAB) and Sareum (LON:SAR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings.

Does the MarketBeat Community believe in FAB or SAR?

Sareum received 28 more outperform votes than Fusion Antibodies when rated by MarketBeat users. However, 68.35% of users gave Fusion Antibodies an outperform vote while only 66.13% of users gave Sareum an outperform vote.

Company	Underperform	Outperform
Fusion Antibodies	Outperform Votes 54 68.35%	Underperform Votes 25 31.65%
Sareum	Outperform Votes 82 66.13%	Underperform Votes 42 33.87%

Which has stronger earnings and valuation, FAB or SAR?

Fusion Antibodies has higher revenue and earnings than Sareum. Sareum is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fusion Antibodies	£2.09M	3.10	-£4.10M	-£4.45	-1.55
Sareum	N/A	N/A	-£5.28M	-£4.22	-3.55

Is FAB or SAR more profitable?

Sareum has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. Fusion Antibodies' return on equity of -137.11% beat Sareum's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fusion Antibodies	-195.95%	-137.11%	-63.78%
Sareum	N/A	-270.25%	-113.80%

Do institutionals and insiders have more ownership in FAB or SAR?

21.0% of Fusion Antibodies shares are owned by institutional investors. 11.4% of Fusion Antibodies shares are owned by company insiders. Comparatively, 5.0% of Sareum shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more volatility and risk, FAB or SAR?

Fusion Antibodies has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Sareum has a beta of -1.08, suggesting that its stock price is 208% less volatile than the S&P 500.

Does the media refer more to FAB or SAR?

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Sareum'saverage media sentiment score.

Company	Overall Sentiment
Fusion Antibodies	Neutral
Sareum	Neutral

Summary

Fusion Antibodies beats Sareum on 9 of the 12 factors compared between the two stocks.